Medicine and Dentistry
Inpatient
100%
Patient
92%
Therapeutic Procedure
66%
Chemotherapy
59%
Non Small Cell Lung Cancer
59%
Analysis
55%
Neoplasm
47%
Epidermal Growth Factor Receptor
37%
Non-Small Cell Lung Cancer
34%
Kidney Metastasis
34%
Pembrolizumab
34%
Observational Study
34%
Pazopanib
34%
Transitional Cell Carcinoma
34%
Pembrolizumab
34%
Overall Survival
30%
Chemoradiotherapy
22%
Gastrostomy
17%
Blood
17%
Percutaneous Endoscopic Gastrostomy
17%
Family
17%
Thrombosis
17%
Bone Scintigraphy
17%
Direct Oral Anticoagulant
17%
Castration Resistant Prostate Cancer
17%
Docetaxel
17%
Venous Thromboembolism
17%
Radium
17%
Central Nervous System
17%
Retreatment
17%
Head and Neck Squamous Cell Carcinoma
17%
Retrospective Study
17%
Nasopharynx Carcinoma
17%
Hazard Ratio
14%
Biological Marker
13%
Arm
13%
Patient with Cancer
11%
Low Molecular Weight Heparin
11%
Pemetrexed
11%
Adverse Event
11%
Intensity Modulated Radiation Therapy
9%
Platinum
8%
Weight Loss
7%
Clinical Trial
6%
Cancer
5%
Anticoagulation
5%
Monotherapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Lazertinib
86%
Chemotherapy
81%
Chemoradiation Therapy
66%
Non Small Cell Lung Cancer
52%
Epidermal Growth Factor Receptor
52%
Cisplatin
35%
Epidermal Growth Factor Receptor
34%
Osimertinib
34%
Progression Free Survival
31%
Neoplasm
28%
Overall Survival
18%
Doxorubicin
17%
Nintedanib
17%
Aprepitant
17%
Zofran
17%
Chemotherapy Induced Nausea and Vomiting
17%
Olanzapine
17%
Docetaxel
17%
Ginger
17%
Sunitinib
17%
Renal Cell Carcinoma
17%
Gefitinib
17%
Transitional Cell Carcinoma
17%
Nasopharynx Carcinoma
17%
Inflammation
17%
Transitional Cell Carcinoma
17%
Tolerability
14%
Circulating Tumor DNA
13%
Toxicity
10%
Infusion Related Reaction
8%
Pemetrexed
8%
Underweight
6%
Adenocarcinoma
6%
Combination Therapy
5%
Disease
5%